Avalo Therapeutics, Inc.

NASDAQ:AVTX

Biotechnology

Healthcare
$6.70 -2.18%

-$0.34 today

Market cap
$387.41M
Beta
0.82
P/E (TTM)
-3.6
EPS (TTM)
-$4.21
52W Low $4.50High $24.27

Volume 1.58M

Average 1.61M

Balance Sheet

Inspect the capital base behind the business.

Assets

$116.46M

FY 2025 · Annual

-22.7% YoY

Liabilities

$33.41M

FY 2025 · Annual

+88.8% YoY

Equity

$83.05M

FY 2025 · Annual

-37.6% YoY

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents54.59M13.17M7.42M134.55M15.86M
Short-term Investments000082.48M
Net Receivables4.8M1.92M136K611K0
Inventory38K20K000
Other Current Assets51K1.31M844K3.73M6.95M
Total Current Assets61.85M16.42M8.4M138.89M105.29M
Property, Plant & Equipment (Net)2.7M2.41M1.97M1.21M460K
Goodwill14.41M14.41M10.5M10.5M10.5M
Intangible Assets38K0000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets1.23M131K131K131K210K
Total Non-current Assets18.37M16.95M12.6M11.84M11.17M
Total Assets80.21M33.37M20.99M150.73M116.46M
Account Payables3.37M2.88M446K283K137K
Short-term Debt05.93M000
Tax Payables00000
Deferred Revenue088K000
Other Current Liabilities4.32M3.18M3.06M3.24M12.41M
Total Current Liabilities19.89M22.11M4.62M6.96M12.94M
Long-term Debt32.83M13.49M002M
Deferred Tax Liabilities113K141K155K270K434K
Deferred Revenue (Non-current)00000
Other Non-current Liabilities4.3M8.54M8.92M10.47M18M
Total Non-current Liabilities37.24M22.17M9.07M10.74M20.47M
Total Liabilities57.13M44.28M13.69M17.7M33.41M
Common Stock9K01K10K18K
Retained Earnings(262.17M)(303.82M)(335.13M)(370.26M)(448.52M)
Accumulated OCI000068K
Other Stockholders Equity00000
Minority Interest00000
Total Equity23.08M(10.92M)7.3M133.03M83.05M
Total Debt33.32M19.95M537K568K2.43M
Net Debt(21.27M)6.78M(6.88M)(133.98M)(13.43M)

Balance Sheet

Assets, liabilities & equity

Cash & Equivalents$25.0M
Short-term Investments$57.0M
Other Current$6.8M
Total Current Assets$88.8M
PP&E (Net)$375.0K
Goodwill$10.5M
Other Non-current$183.0K
Total Non-current Assets$11.1M
Total Assets$99.9M

Analysis

Selected assets total $99.9M for Latest. The largest visible component is Short-term Investments at $57.0M, about 57.1% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13GSC 13G filingNov 13, 2026
SC 13GSC 13G filingNov 10, 2026
SC 13G/ASC 13G/A filingNov 6, 2026
S-3ASRS-3ASR filingNov 5, 2026
SC 13G/ASC 13G/A filingNov 5, 2026

How much cash does AVTX have?

Avalo Therapeutics, Inc. (AVTX) reported $15.86M in cash and equivalents in fiscal 2025.

How much debt does AVTX carry?

Avalo Therapeutics, Inc. (AVTX) reported $2.43M of total debt, with net debt of -$13.43M.